Pravastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H36O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KXO2KT9N0G, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as pravastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Pravastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10004MIG. The term PRAVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules pravastatin in its Anatomical Therapeutic Chemical (ATC) Classification. PRAVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pravastatin under HS 29181985 and SITC 51392. As of Q4 2014, PRAVASTATIN remains the US FDA Preferred Term for this commodity. Pravastatin bears US NLM identifiers UMLS ID C0085542 and NCI Concept Code C62070. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.